Infectious Disease Clinical Research

Infectious Diseases

Accelerate your infectious disease clinical program with an experienced provider of CRO solutions

Each year, millions of people around the world contract an infectious disease. Your drug development program — and the patients who need treatment — can’t be left to chance.

Developing treatments to prevent the spread of infectious diseases requires more than a commitment to global public health. You need a strong clinical development strategy, supported by a contract research organization (CRO), to navigate the complexities and urgency of infectious disease clinical trials at every stage.

You can accelerate your program with our infectious disease team, who deliver proven experience and expertise through each phase of drug development. With teams on the ground in more than 80 countries and access to thousands of experienced sites, we boost your infectious disease clinical trial with speed and agility — getting it started quickly and keeping it on track throughout.

Whether you are developing treatments for influenza, RSV, hepatitis, HIV, or an emerging pathogen, when you choose us as your infectious disease CRO partner, you gain:

  • Subject matter expertise across a broad range of infectious disease indications 
  • Resources to streamline the development process from Phase I through peri- and post-approval
  • Access to diverse patients worldwide
  • Seamless integration with our laboratory teams, who provide data with immediacy, enabling you to make faster, more informed decisions during the trial
  • Digital and decentralized solutions that increase patient engagement and retention and enhance the patient experience

Understanding evolving regulations is essential to success in infectious disease clinical research. Our extensive regulatory experience derives from our collaborations with multiple government agencies including the National Institutes of Health, the U.S. Department of Defense, Biomedical Advanced Research and Development Authority, and the Centers for Disease Control and Prevention.

Powering breakthroughs in infectious disease research

Over the past five years, drug developers have turned to us for our infectious disease expertise, strong network of sites and patient-centric solutions that move drug development programs forward.

0 +

Trials for commercial and government customers

0 +

Global sites supporting infectious disease trials

0 +

Patients enrolled in our infectious disease trials

Infectious disease research expertise

Infectious disease clinical research requires a deep understanding of the complexities of the diseases and the people they impact. That understanding comes with experience.

Hear from our experts about how they built their depth of experience in HIV, antibacterial, RSV, and hepatitis B clinical research, and how they use that knowledge to enable our customers’ advancements in treatments.

Global investigator network for infectious disease research

Access to a global investigator database that includes infectious disease specialists is vital. With the PPD™ clinical research business of Thermo Fisher Scientific, you’ll be connected to infectious disease specialists in:

  • Bacterial, fungal and parasitic diseases
  • Chronic hepatitis B and C
  • COVID-19
  • HIV
  • Influenza
  • Pediatric indications

You can count on us to deliver investigators and sites with proven trial experience.

And patients remain at the center of your clinical development strategy. Our digital and decentralized trial solutions are designed to increase clinical trial access for patients while improving their overall experience, meaning better patient engagement and retention for your trial.

Interested in vaccine development for your infectious disease program? See how we can help

HIV drug development and research leader

Research into treatments for HIV remains a priority for drug developers. Whether you are pursuing a short- or long-term HIV trial or a concomitant program for a Phase III study, we can partner with you to achieve success. Our extensive experience includes trials addressing:

  • Opportunistic infections
  • Co-infections
  • Highly active antiretroviral therapies (HAART)

Drug developers — from both the government and private sector — have selected us as their infectious disease CRO partner to conduct their HIV studies. When developing your HIV clinical development strategy, you need access to high-quality data and a CRO that will explore transformative approaches to HIV treatment studies. With us, your strategy will be tailored to your unique needs and mapped out approaches to include traditionally overlooked populations in HIV trials.

Our COVID-19 experience

When a pandemic strikes, you want an experienced infectious disease CRO at the ready. As COVID-19 spread across the globe, drug developers sought out partners that possessed broad and relevant capabilities to guide treatments from clinical trials to post-approval. Together with sponsors, we quickly gained valuable, specific, and extensive experience in the management of global COVID-19 programs, and are prepared to respond to any future pandemics. 

The success of our COVID-19 programs was built upon a strong foundation of infectious disease experience, a commitment to collaboration to rapidly develop solutions, and access to end-to-end solutions. Position your future coronavirus clinical trials by leveraging our depth of expertise and capabilities, including:

  • Regulatory
  • Medical communications
  • Clinical monitoring
  • Laboratories
  • Digital solutions
0 +

Global COVID-19 treatment studies

0 +


0 +

Patients and subjects


Robust capabilities for COVID-19

The urgent call for COVID-19 treatments accelerated our customers’ clinical development needs — and we responded. Learn how we enabled Gilead to initiate trials for remdesivir and collaborated with U.K. health research agencies on a Roche COVID-19 study.

When responding to a global public health emergency, you need a provider of CRO solutions with proven experience and specialized capabilities to drive your treatment program forward. Our COVID-19-specific capabilities include:

  • Therapeutic and regulatory experts to enable you to navigate evolving global regulatory requirements
  • Epidemiological modeling to forecast COVID-19 caseloads at various geographical levels as part of our feasibility approach
  • Industry-leading therapeutic and diagnostic sites with surge capacity and strategies to expedite patient recruitment
  • Proven global clinical supplies services with direct-to-patient options
  • Established risk-based monitoring plans that include enhanced centralized monitoring to ensure high-quality data in a fully remote context
  • Near real-time safety assessment data available through our Preclarus® patient data dashboard
  • Digital and decentralized solutions to reduce the need for on-site interactions while creating efficiencies for providers, sites and patients
  • Globally integrated GMP, bioanalytical, biomarker and central laboratories and in-country testing to meet regulatory requirements
  • Extensive post-approval solutions for evidence of real-world safety and effectiveness, including registries, non-interventional and interventional Phase IV studies
  • Strategic and operational delivery of post-acute COVID syndrome and special population studies, including pregnancy and pediatrics

Laboratory services for infectious disease clinical trials

From safety testing to microbiology and molecular genomic testing, infectious disease trials require a broad array of laboratory services. We offer globally integrated GMP, bioanalytical, biomarker and central laboratories that support trials of all sizes.

  • Extensive virology testing, including real-time polymerase chain reaction, viral load, genotyping and single nucleotide polymorphism analysis
  • The capability to culture, quantitate, identify and determine antibiotic susceptibility and resistance for aerobic and anaerobic organisms
  • A flexible approach to microbiology testing, performing disk diffusion and/or broth dilution assays to establish antibiotic minimum inhibitory concentration and breakpoints

Partner with us to advance your infectious disease program.